Norwegian University of Science & Technology

Diamyd's Antigen-Specific Immunotherapy Shows Promise in LADA Patients

a month ago

• Diamyd Medical's Diamyd® immunotherapy demonstrates disease-modifying potential in adults with Latent Autoimmune Diabetes in Adults (LADA) in a recent pilot trial. • The GADinLADA trial, featuring three intralymphatic injections of Diamyd®, reported no treatment-related severe adverse events, confirming the therapy's safety profile. • Results indicated preservation of insulin-producing capacity, particularly in HLA DR3-DQ2 positive patients, suggesting a precision medicine approach to LADA treatment. • All LADA patients in the trial remained insulin-independent at least 12 months post-treatment, highlighting the potential for long-term benefits.